The latest price target for Arcutis Biotherapeutics (NASDAQ:ARQT) was reported by Goldman Sachs on February 27, 2025. The analyst firm set a price target for $15.00 expecting ARQT to rise to within 12 months (a possible 0.81% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Arcutis Biotherapeutics (NASDAQ:ARQT) was provided by Goldman Sachs, and Arcutis Biotherapeutics maintained their neutral rating.

The last upgrade for Arcutis Biotherapeutics Inc happened on January 3, 2024 when Mizuho raised their price target to $8. Mizuho previously had a neutral for Arcutis Biotherapeutics Inc.

The last downgrade for Arcutis Biotherapeutics Inc happened on November 8, 2023 when JonesTrading changed their price target from N/A to N/A for Arcutis Biotherapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcutis Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcutis Biotherapeutics was filed on February 27, 2025 so you should expect the next rating to be made available sometime around February 27, 2026.

While ratings are subjective and will change, the latest Arcutis Biotherapeutics (ARQT) rating was a maintained with a price target of $13.00 to $15.00. The current price Arcutis Biotherapeutics (ARQT) is trading at is $14.88, which is within the analyst’s predicted range.